Analyst Research

Report Title Price
Provider: S&P Capital IQ Quantitative Report
$127.00
Provider: Pechala's Reports
$15.00
Provider: Pechala's Reports
$25.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Achillion Pharmaceuticals Inc achieves 100 pct sustained virologic response rate from an eight week phase 2 trial


Friday, 15 Aug 2014 06:59am EDT 

Achillion Pharmaceuticals Inc:Says interim results from ongoing Phase 2 proxy study evaluating ACH-3102, Achillion's second-generation NS5A inhibitor, in combination with sofosbuvir, without ribavirin, for eight weeks of treatment in patients with treatment-na├»ve genotype 1 chronic hepatitis C virus (HCV) infection.Says of the 12 patients treated, 100 percent (n=12/12) remained HCV RNA undetectable four weeks after completing therapy (SVR4).Says based upon these results, 12 additional patients will begin treatment with six weeks of once daily ACH-3102 and sofosbuvir.Says ACH-3102 continues to demonstrate good safety and tolerability through three Phase 2 studies.Says primary objective of the study is determination of sustained viral response 12 weeks (SVR12) after the completion of therapy\.Says Twelve patients completed eight weeks of treatment consisting of 50 mg of ACH-3102 and 400 mg of sofosbuvir administered once daily while observational patients received no drug during this phase of the trial.Says Ten of 12 patients receiving eight weeks of treatment had genotype 1a HCV with median HCV RNA at baseline of 7.22 log10(range 5.5 - 7.8 log10).Says no on-treatment viral breakthrough or post-treatment viral relapse has been observed to date.Says ACH-3102 and sofosbuvir were well tolerated with no significant adverse events, ECG findings, or lab abnormalities observed during treatment. 

Company Quote

11.5
-0.45 -3.77%
19 Sep 2014